Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISLB 2022 | Potential of liquid biopsy as a monitoring tool

Adam Widman • 19 Oct 2022
ISLB 2022
General Lung Cancer Melanoma Skin Cancer

Adam Widman, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the current and future applications of liquid biopsy as a monitoring tool and highlights its use as a non-invasive tool to help with ongoing treatment decisions. This interview took place at the International Society of Liquid Biopsy (ISLB) 2022 congress in Miami, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Adam Widman

1:49
Using machine learning to enhance liquid biopsy
Adam Widman • 19 Oct 2022
1:36
Potential of machine learning in liquid biopsy
Adam Widman • 19 Oct 2022

Related Videos

2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
1:20
Can ctDNA guide the treatment decision making process in melanoma?
Christoffer Gebhardt • 9 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals